NCCN task force report: Prevention and management of mucositis in cancer care

William Bensinger, Mark Schubert, Kie Kian Ang, David Brizel, Elizabeth Brown, June G. Eilers, Linda Elting, Bharat B. Mittal, Mark A. Schattner, Ricardo Spielberger, Nathaniel S. Treister, Andy M. Trotti

Research output: Contribution to journalReview article

132 Citations (Scopus)

Abstract

Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and radiotherapy with or without concurrent chemotherapy of head and neck cancer. Research into both preventive and management strategies has lagged behind research into the common cancer treatment-related morbidities of nausea, vomiting, and cytopenias. This disparity is related to the complex risk assessment of multifactorial patient and treatment factors and different techniques of rating mucositis. In addition, relatively few clinical trials have focused on mucositis as a specific outcome. Currently, the only effective preventive strategies include the use of palifermin to prevent OM in the setting of hematopoietic stem cell transplantation and oral cryotherapy used in conjunction with bolus 5-FU, melphalan, or edatrexate. For the most part, managing OM relies on supportive care and symptom palliation. However, OM is a common problem associated with significant patient morbidity and increased resource use. The magnitude of the problem demands innovative approaches based on expert judgment as evidence accumulates to support specific recommendations. To improve this situation, the NCCN convened a multidisciplinary task force to address key issues. This report integrates expert judgment with a review of key literature on risk assessment, prevention, and treatment strategies, and provides recommendations for the overall management of OM.

Original languageEnglish (US)
Pages (from-to)S1-S21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue numberSUPPL. 1
StatePublished - Feb 1 2008

Fingerprint

Stomatitis
Mucositis
Advisory Committees
Neoplasms
Drug Therapy
Fibroblast Growth Factor 7
Morbidity
Cryotherapy
Melphalan
Second Primary Neoplasms
Hematopoietic Stem Cell Transplantation
Head and Neck Neoplasms
Research
Fluorouracil
Nausea
Vomiting
Radiotherapy
Therapeutics
Clinical Trials

Keywords

  • Chemotherapy
  • Mucositis
  • NCCN Task Force Report
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Bensinger, W., Schubert, M., Ang, K. K., Brizel, D., Brown, E., Eilers, J. G., ... Trotti, A. M. (2008). NCCN task force report: Prevention and management of mucositis in cancer care. JNCCN Journal of the National Comprehensive Cancer Network, 6(SUPPL. 1), S1-S21.

NCCN task force report : Prevention and management of mucositis in cancer care. / Bensinger, William; Schubert, Mark; Ang, Kie Kian; Brizel, David; Brown, Elizabeth; Eilers, June G.; Elting, Linda; Mittal, Bharat B.; Schattner, Mark A.; Spielberger, Ricardo; Treister, Nathaniel S.; Trotti, Andy M.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. SUPPL. 1, 01.02.2008, p. S1-S21.

Research output: Contribution to journalReview article

Bensinger, W, Schubert, M, Ang, KK, Brizel, D, Brown, E, Eilers, JG, Elting, L, Mittal, BB, Schattner, MA, Spielberger, R, Treister, NS & Trotti, AM 2008, 'NCCN task force report: Prevention and management of mucositis in cancer care', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. SUPPL. 1, pp. S1-S21.
Bensinger, William ; Schubert, Mark ; Ang, Kie Kian ; Brizel, David ; Brown, Elizabeth ; Eilers, June G. ; Elting, Linda ; Mittal, Bharat B. ; Schattner, Mark A. ; Spielberger, Ricardo ; Treister, Nathaniel S. ; Trotti, Andy M. / NCCN task force report : Prevention and management of mucositis in cancer care. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. SUPPL. 1. pp. S1-S21.
@article{e2b322f904fd4f6cb8f48064f66a0ff3,
title = "NCCN task force report: Prevention and management of mucositis in cancer care",
abstract = "Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and radiotherapy with or without concurrent chemotherapy of head and neck cancer. Research into both preventive and management strategies has lagged behind research into the common cancer treatment-related morbidities of nausea, vomiting, and cytopenias. This disparity is related to the complex risk assessment of multifactorial patient and treatment factors and different techniques of rating mucositis. In addition, relatively few clinical trials have focused on mucositis as a specific outcome. Currently, the only effective preventive strategies include the use of palifermin to prevent OM in the setting of hematopoietic stem cell transplantation and oral cryotherapy used in conjunction with bolus 5-FU, melphalan, or edatrexate. For the most part, managing OM relies on supportive care and symptom palliation. However, OM is a common problem associated with significant patient morbidity and increased resource use. The magnitude of the problem demands innovative approaches based on expert judgment as evidence accumulates to support specific recommendations. To improve this situation, the NCCN convened a multidisciplinary task force to address key issues. This report integrates expert judgment with a review of key literature on risk assessment, prevention, and treatment strategies, and provides recommendations for the overall management of OM.",
keywords = "Chemotherapy, Mucositis, NCCN Task Force Report, Radiotherapy",
author = "William Bensinger and Mark Schubert and Ang, {Kie Kian} and David Brizel and Elizabeth Brown and Eilers, {June G.} and Linda Elting and Mittal, {Bharat B.} and Schattner, {Mark A.} and Ricardo Spielberger and Treister, {Nathaniel S.} and Trotti, {Andy M.}",
year = "2008",
month = "2",
day = "1",
language = "English (US)",
volume = "6",
pages = "S1--S21",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "SUPPL. 1",

}

TY - JOUR

T1 - NCCN task force report

T2 - Prevention and management of mucositis in cancer care

AU - Bensinger, William

AU - Schubert, Mark

AU - Ang, Kie Kian

AU - Brizel, David

AU - Brown, Elizabeth

AU - Eilers, June G.

AU - Elting, Linda

AU - Mittal, Bharat B.

AU - Schattner, Mark A.

AU - Spielberger, Ricardo

AU - Treister, Nathaniel S.

AU - Trotti, Andy M.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and radiotherapy with or without concurrent chemotherapy of head and neck cancer. Research into both preventive and management strategies has lagged behind research into the common cancer treatment-related morbidities of nausea, vomiting, and cytopenias. This disparity is related to the complex risk assessment of multifactorial patient and treatment factors and different techniques of rating mucositis. In addition, relatively few clinical trials have focused on mucositis as a specific outcome. Currently, the only effective preventive strategies include the use of palifermin to prevent OM in the setting of hematopoietic stem cell transplantation and oral cryotherapy used in conjunction with bolus 5-FU, melphalan, or edatrexate. For the most part, managing OM relies on supportive care and symptom palliation. However, OM is a common problem associated with significant patient morbidity and increased resource use. The magnitude of the problem demands innovative approaches based on expert judgment as evidence accumulates to support specific recommendations. To improve this situation, the NCCN convened a multidisciplinary task force to address key issues. This report integrates expert judgment with a review of key literature on risk assessment, prevention, and treatment strategies, and provides recommendations for the overall management of OM.

AB - Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and radiotherapy with or without concurrent chemotherapy of head and neck cancer. Research into both preventive and management strategies has lagged behind research into the common cancer treatment-related morbidities of nausea, vomiting, and cytopenias. This disparity is related to the complex risk assessment of multifactorial patient and treatment factors and different techniques of rating mucositis. In addition, relatively few clinical trials have focused on mucositis as a specific outcome. Currently, the only effective preventive strategies include the use of palifermin to prevent OM in the setting of hematopoietic stem cell transplantation and oral cryotherapy used in conjunction with bolus 5-FU, melphalan, or edatrexate. For the most part, managing OM relies on supportive care and symptom palliation. However, OM is a common problem associated with significant patient morbidity and increased resource use. The magnitude of the problem demands innovative approaches based on expert judgment as evidence accumulates to support specific recommendations. To improve this situation, the NCCN convened a multidisciplinary task force to address key issues. This report integrates expert judgment with a review of key literature on risk assessment, prevention, and treatment strategies, and provides recommendations for the overall management of OM.

KW - Chemotherapy

KW - Mucositis

KW - NCCN Task Force Report

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=38549100593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549100593&partnerID=8YFLogxK

M3 - Review article

C2 - 18289497

AN - SCOPUS:38549100593

VL - 6

SP - S1-S21

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - SUPPL. 1

ER -